Free Trial
NYSE:EBS

Emergent Biosolutions Q2 2025 Earnings Report

Emergent Biosolutions logo
$7.34 +0.01 (+0.14%)
Closing price 07/11/2025 03:59 PM Eastern
Extended Trading
$7.28 -0.06 (-0.76%)
As of 07/11/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Emergent Biosolutions EPS Results

Actual EPS
N/A
Consensus EPS
$0.21
Beat/Miss
N/A
One Year Ago EPS
N/A

Emergent Biosolutions Revenue Results

Actual Revenue
N/A
Expected Revenue
$148.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Emergent Biosolutions Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
5:00PM ET

Conference Call Resources

Emergent Biosolutions Earnings Headlines

"I'm risking my reputation on this"
Behind closed doors, away from the mainstream media's eyes, the smartest minds in crypto are all seeing the same signals. They're positioning themselves for something unprecedented. And after 17 million podcast downloads and over 600 insider interviews, I finally connected all the dots… What I discovered was so explosive, so potentially life-changing, that I had to put it all in a book.
See More Emergent Biosolutions Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Emergent Biosolutions? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Emergent Biosolutions and other key companies, straight to your email.

About Emergent Biosolutions

Emergent Biosolutions (NYSE:EBS) is a global life sciences company dedicated to the development, manufacture and delivery of vaccines and antibody therapies that address public health threats. The company’s portfolio encompasses a range of biodefense and infectious disease countermeasures, including the U.S.‐licensed anthrax vaccine BioThrax® and the smallpox vaccine ACAM2000®. In addition to its proprietary products, Emergent offers contract development and manufacturing services for governments and commercial partners, with specialized capabilities in large‐scale biologics production.

Since its founding in 1998 and subsequent initial public offering in 2006, Emergent has expanded through strategic acquisitions such as Cangene Corporation and Adapt Pharma, broadening its product offerings to include treatments for opioid overdose and other critical care needs. The company’s Infectious Disease segment has introduced naloxone nasal spray under the Narcan® brand, demonstrating its commitment to addressing both biodefense and emerging public health crises. Emergent’s vaccine development pipeline also targets diseases such as Zika and chikungunya, reflecting its focus on readiness for future outbreaks.

Headquartered in Gaithersburg, Maryland, Emergent BioSolutions serves customers across North America, Europe and the Asia-Pacific region, with key government clients including the U.S. Department of Health and Human Services and various defence agencies. Its manufacturing facilities, located in the United States and Puerto Rico, are designed to meet stringent regulatory and security standards required for national stockpile products. The company has also forged partnerships with global health organizations to support vaccine access in emerging markets.

Under the leadership of President and Chief Executive Officer Robert G. Kramer Jr., Emergent’s executive team brings deep expertise in biotechnology, government contracting and large‐scale manufacturing. Guided by a board of directors with backgrounds in public health, finance and regulatory affairs, the company continues to invest in research and development, facility expansion and strategic collaborations to strengthen global preparedness against current and future health threats.

View Emergent Biosolutions Profile

More Earnings Resources from MarketBeat